Roder, Joanna
Maguire, Laura
Georgantas, Robert III
Roder, Heinrich
Article History
Received: 29 March 2021
Accepted: 29 June 2021
First Online: 8 July 2021
Declarations
:
: The study was approved by institutional review boards and independent ethics committees at each participating site (San Raffaele Scientific Institute, Milan, Italy; University of Turin, AOU San Luigi Orbassano, Turin, Italy; Azienda Opsedaliera Treviglio, Treviglio, Italy; IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero in Vulture, Italy; Villa Scassi Hospital, Genoa, Italy; Azienda Ospedaliera San Martino University, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; European Institute of Oncology, Milan, Italy; San Camillo High Specialization Hospital, Rome, Italy; National Cancer Institute of Aviano, Aviano, Italy; Fondazione Istituto San Raffaele di G. Giglio di Cefalu, Cefalu, Italy; Azienda “Complesso Ospedaliero San Fillippo Neri”, Rome, Italy; Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy; Azienda Ospedaliera Ospedale S. Anna, Como, Itlay; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy). All patients provided written informed consent.
: Not applicable.
: HR and JR are inventors on patents concerning the VeriStrat test, all assigned to Biodesix, Inc. All authors are current employees of Biodesix, Inc. and have stock options and/or own shares in Biodesix, Inc.